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Abstract 
Background: Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine (SP) is widely 
implemented in sub-Saharan Africa for the prevention of malaria in pregnancy and adverse birth outcomes. However, 
in areas of intense SP resistance, the efficacy of IPTp may be compromised.
Methods: A cross-sectional study among 915 delivering women (728 analysable live singleton deliveries) was con-
ducted in Fort Portal, western Uganda, to assess associations of reported IPTp use, Plasmodium falciparum infection, 
maternal anaemia, low birth weight, and preterm delivery, and to estimate the degree of SP resistance as reflected by 
pfdhfr/pfdhps mutations.
Results: Plasmodium falciparum infection was detected by PCR in 8.9 % and by microscopy of placental blood 
samples in 4.0 %. Infection was significantly associated with stillbirth, early neonatal death, anaemia, low birth 
weight, and pre-term delivery. Eighty percent of the women had taken at least one dose of IPTp, and more than half 
had taken two doses. As compared to women without chemoprophylaxis against malaria, IPTp had no significant 
influence on the presence of P. falciparum infection (13.8 vs. 9.6 %, P = 0.31). Nor was it associated with reductions 
in anaemia, low birth weight or preterm delivery. P. falciparum with intense SP resistance (pfdhfr/pfdhps quintuple or 
sextuple mutations) were observed in 93 % (pfdhps 581G, 36 %), and the additional high resistance allele pfhdr 164L 
in 36 %.
Conclusions: In Fort Portal, Uganda, reported use of IPTp with SP does not provide an observable benefit. The 
molecular markers of P. falciparum indicate high grade SP resistance reaching the threshold set by WHO for the dis-
continuation of IPTp with SP. Alternative approaches for the prevention of malaria in pregnancy are urgently needed.
© 2015 Braun et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Despite the implementation of intermittent preven-
tive treatment in pregnancy (IPTp) with sulfadoxine–
pyrimethamine (SP) in sub-Saharan Africa starting more 
than two decades ago, malaria in pregnancy continues to 
be a major public health problem. Pregnant women form 
a specific risk group for Plasmodium falciparum infec-
tion, malaria and related consequences, which include 
abortion, stillbirth, maternal anaemia, low birth weight 
(LBW), preterm delivery, and, annually, up to 200,000 
infant deaths [1]. In highly endemic regions, primiparae 
are at particular risk due the lack of specific immunity 
preventing the placental sequestration of pregnancy-spe-
cific P. falciparum strains. Placental sequestration gives 
rise to local inflammation and also may result in placen-
tal infection in the absence of detectable peripheral blood 
infection [2–4].
Coverage with IPTp is low (<25  %) in African coun-
tries with an IPTp policy [5]. Moreover, the effectiveness 
of IPTp critically depends on parasite sensitivity to the 
drug, but SP resistance of P. falciparum has spread across 
Africa and intensified particularly in the East of the 
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continent [6, 7]. In 2012, WHO modified the recommen-
dation of two doses of IPTp with SP during pregnancy in 
areas of moderate to high transmission towards adminis-
tration at each scheduled antenatal care (ANC) visit but 
at least 1 month apart [8]. This accords with the observa-
tion of less malaria and better birth outcomes using three 
or more doses of SP as compared to the standard two-
dose regimen [9]. While the effectiveness of this approach 
has yet to be proven in areas of intense resistance, data 
from East Africa suggest at least partial failure of IPTp 
with SP in improving overall pregnancy outcomes [10–
13]. In addition, in areas of intense SP resistance in Tan-
zania, IPTp among infected women was associated with 
increased placental parasite density and inflammation 
[14] as well as an increased risk of severe malaria in the 
offspring [15], and infections with highly resistant para-
sites were associated with lower birth weight [16].
Resistance to SP is conferred by mutations in the P. 
falciparum dihydrofolate reductase (pfdhfr) and dihy-
dropteroate synthase (pfdhps) genes: a triple mutation 
of pfdhfr (108N -5I1-59R) combined with pfdhps muta-
tions 437G and 540E (pfdhfr/pfdhps quintuple mutant) 
is predictive for SP treatment failure in children, even 
more so in case of an additional pfdhps 581 muta-
tion (sextuple mutant). pfdhfr 164L is linked with high 
grade SP resistance [6, 17–19]. Recent work has shown 
that the effectiveness of IPTp declines with an increas-
ing population prevalence of the pfdhps 540E mutation 
(representing the pfdhfr/pfdhps quintuple mutation) 
even though some effect on birth weight remains even 
at very high prevalence. Increasingly, the pfdhfr/pfdhps 
sextuple mutation including the pfdhps 581 variant is 
considered an informative marker on whether IPTp 
might be compromised or not [20, 21]. In line with that, 
a recent study from Malawi reported failure of parasite 
suppression by IPTp in the presence of sextuple-mutant 
parasites [22].
In Uganda, policy recommendation is at least two 
doses of IPTp in pregnancy [23]. In the central part of 
the country, quintuple and sextuple pfdhfr/pfdhps muta-
tions combined were recently found in >90 % of P. falci-
parum infecting pregnant women at first ANC visit [24], 
and in the eastern part, more than a quarter of deliver-
ing women had evidence of active placental P. falciparum 
infection despite previous intake of ≥2 doses of SP [13]. 
In the latter region, IPT of school children with SP did 
not provide any benefit over placebo [25]. In the present 
study, the effectiveness of IPTp with SP in the western 
highland region of Fort Portal was estimated in a cross 
sectional study looking at effects on infection, anaemia, 
LBW, and preterm delivery as well as on the pattern of 
pfdhfr/pfdhps alleles.
Methods
Fort Portal, located at 1500  m altitude, is a commu-
nity of some 55,000 inhabitants and capital of the west-
ern Kabarole district, close to the border of DR Congo. 
Twenty years ago, an altitude of 1500  m in this district 
represented a threshold between hypo- and mesoen-
demic conditions [26]. The 2014 malaria indicator survey 
reports a prevalence of malaria parasites among children 
in the larger mid-Western region of 18 % [27]. The Holy 
Family Virika Hospital in Fort Portal is a private (Cath-
olic Church) not-for-profit health facility and has a bed 
capacity of 155. It provides services to patients from 
Kabarole and surrounding districts and thereby supple-
ments the governmental Fort Portal Regional Referral 
Hospital (330 beds). From February to December 2013, 
adult women attending Virika Hospital for delivery 
were asked to participate in the present cross-sectional 
study and recruited after informed written consent was 
obtained. The study protocol was reviewed and approved 
by the Higher Degrees, Research, and Ethics Committee, 
College of Health Sciences, Makerere University, Kam-
pala, and by the Uganda National Council for Science 
and Technology.
All women were clinically examined. Fever was defined 
as an axillary temperature ≥37.5 °C. Obstetric and medi-
cal history was documented, as were socio-economic 
data. Participation in a programme on prevention of 
mother-to-child-transmission of HIV (PMTCT) was 
noted. Data on intake of SP or other anti-malarial drugs 
was verified on ANC cards. Venous peripheral blood was 
collected into EDTA; blood from the intervillous space 
was collected with a syringe containing EDTA following 
incision into the maternal surface of the placenta. Hae-
moglobin (Hb) was measured by a HemoCue photometer 
(Ångelholm, Sweden) and anaemia defined as Hb <11.5 g/
dL increasing the threshold by +0.5  g/dL to account 
for altitude [28]. Birth weight and gestational age were 
assessed within 24 h after delivery. LBW was defined as 
a birth weight <2500  g and preterm delivery as gesta-
tional age <37 weeks applying the simple morphological 
Finnström score [29]. Malaria parasites were counted 
microscopically on Giemsa-stained thick blood films per 
500 white blood cells for peripheral samples and per 100 
high-power fields for placental samples. Following DNA 
extraction of peripheral blood samples (QIAmp, Qiagen, 
Germany), semi-nested PCR assays were performed for 
the diagnosis of P. falciparum and other species [30]. If 
not otherwise indicated, P. falciparum infection here-
inafter refers to infection as detected by PCR. For P. 
falciparum resistance marker typing, restriction frag-
ment length polymorphisms of PCR-generated ampli-
cons identified mutations of pfdhfr (N51I, C59R, S108N, 
I164L) and pfdhps (A437G, K540E, A581G) [31]. Isolates 
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with mixed alleles, i.e., both wildtype and mutation pre-
sent, were considered mutant. Laboratory strains 3D7, 
HB3 and Dd2 served as controls.
Women were grouped into primiparae, parae 2 and 
3, and multiparae (>3 previous deliveries). Geometric 
mean parasite densities (GMPDs) and 95  % confidence 
intervals (95  % CIs) were calculated. Continuous vari-
ables were compared between groups by t test, analysis 
of variance, Mann–Whitney U test, and Kruskal–Wallis 
test as applicable. Associations between categorical vari-
ables were identified by χ2 test or Fisher’s exact test, and 
odds ratios (ORs) were calculated. Multivariate logis-
tic regression with stepwise removal of factors found to 
be not associated in multivariate analysis (P > 0.05) was 
used to identify independent predictors of P. falciparum 
infection. A P value of <0.05 was considered statistically 
significant.
Results
Between February and December 2013, 915 delivering 
women were recruited and 945 babies (885 singles, 60 
twins) were born, of whom 45 (4.9  %) were born dead. 
The characteristics of the 728 live singleton deliveries 
with available P. falciparum infection status by PCR are 
shown in Table  1. Data on chemoprevention was veri-
fied by checking ANC cards in 98.3 % (676/688) of these 
women. Most women originated from the local Kabarole 
district, and Mutooro ethnicity predominated. Travel to 
the hospital took a median of approximately 1 h. Almost 
one third benefited from a coverage programme for hos-
pital costs. Unmarried mothers were common among 
primiparae but rare in multiparae who at the same time 
showed comparatively lower levels of formal educa-
tion than primiparae. Multiparae showed reduced proxy 
parameters of socio-economic status, e.g., tap water or 
electricity on the premises.
Almost half of the women had been referred to the 
hospital for delivery, and 12 % participated in a PMTCT 
programme. The number of previous antenatal care visits 
was similar among primiparae and parae 2 and 3 but less 
in multiparae. Eighty percent of the women had taken at 
least one dose of IPTp (adding 3.5 % of those taking both 
IPTp and cotrimoxazole), and more than half had taken 
two doses. No chemoprophylaxis and daily cotrimoxa-
zole were taken by each 8 % of the women. Cotrimoxazole 
intake was less common among primiparae whereas IPTp 
was non-significantly more frequent. Almost two thirds 
of women stated to have used a bed net in the previous 
night and one in four women reported to have received 
treatment for malaria during pregnancy, without differ-
ences by parity. Fever was rare. Anaemia (29 %) affected 
women of all parities. Birth weight increased with 
increasing parity and this was reflected by a respective 
trend towards less LBW. Preterm delivery was increased 
in primiparae (P = 0.03).
Prevalence of Plasmodium falciparum infection
Plasmodium falciparum was detected in peripheral 
blood by PCR in 8.9  % (65/728) and by microscopy in 
2.9 % (20/682). The geometric mean parasite density was 
1986/µL (95 % CI, 602–6553). Placental parasitaemia was 
observed by microscopy in 4.0 % (27/676). 56.9 % (37/65) 
of the infections were submicroscopic, i.e., reflected 
by a positive PCR but negative microscopy result of 
peripheral or placental blood. Irrespective of diagnostic 
method, infection prevalence slightly and non-signifi-
cantly declined with increasing parity (Fig. 1). Non-falci-
parum parasites were rare (seven Plasmodium malariae, 
one Plasmodium ovale) and not related to parity.
Manifestation of Plasmodium falciparum infection
In all women available for analysis, P. falciparum infec-
tion (PCR) was associated with increased odds of still-
birth: it occurred in 4.3 % (31/716) of non-infected and in 
10.7 % (8/75) of infected mothers (OR, 2.64; 95 % CI, 1.1–
6.3; P = 0.02). This association was pronounced for infec-
tions detected by placental microscopy [4.3  % (35/808) 
vs. 14.7 % (5/34); OR, 3.81; 95 % CI, 1.1–10.8; P = 0.02] 
but non-significant for submicroscopic infections (OR, 
2.33; 95 % CI, 0.6–7.1; P = 0.12).
Among women with live singleton delivery, 13 children 
died within 24  h of delivery. In 30.8  % (4/13) of these, 
maternal P. falciparum infection had been observed as 
compared to 8.5 % (61/715) among mothers of surviving 
children (OR, 4.77; 95 % CI, 1.0–17.6; P = 0.02). More-
over, P. falciparum infection was associated with each 
more than doubled odds of anaemia, LBW and preterm 
delivery (Table 2). Correspondingly, in infected (PCR) as 
compared to non-infected mothers, median Hb concen-
tration, median birth weight, and mean gestational age 
were reduced by 1.0 g/dL (P < 0.0001), 130 g (P = 0.03), 
and 1 week (P =  0.01), respectively. Anaemia and LBW 
were not increased in women with submicroscopic infec-
tion, but preterm delivery showed a respective trend 
(Table 2).
Impact of intermittent preventive treatment
IPTp had no significant influence on the presence of P. 
falciparum infection. Nor was it associated with reduc-
tions in anaemia, LBW or preterm delivery (Table  3). 
Correspondingly, P. falciparum infection in women 
using IPTp was associated with reductions in median 
Hb concentration, median birth weight, and mean gesta-
tional age of 0.85 g/dL (P =  0.0008), 207 g (P =  0.004), 
and 1.1  weeks (P  =  0.0003), respectively. Stratification 
by parity did not change these overall findings (Table 4). 
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Moreover, infection prevalence was not reduced in 
women having taken two doses of IPTp (10.9 %, 41/376) 
as compared to one dose (6.8 %, 12/176). Timing of last 
IPTp intake (weeks ago) and infection were not associ-
ated (P = 0.93). In women on cotrimoxazole or IPTp plus 
cotrimoxazole, infection prevalence was substantially 
reduced but not significantly so (Table 3). 
Factors associated with Plasmodium falciparum infection
In univariate analysis, the odds of P. falciparum infection 
declined with age, presence of electricity in the house-
hold, bed net ownership, bed net usage in the preceding 
night, and Mutooro ethnicity, and increased with referral 
to hospital for delivery and travel distance to the hospi-
tal. In multivariate analysis, referral and travel distance 
Table 1 Characteristics of 728 women with live singleton deliveries
Parameter All Primiparae Parae II and III Multiparae (>III) P
No. (%) 100 (728) 31.6 (229/725) 37.0 (268/725) 31.4 (228/725)
Age (years; median, range) 25 (18–42) 20 (18–35) 24 (18–39) 30 (20–42) <0.0001
Residence in Kabarole district (%, No.) 76.9 (498/648) 75.6 (155/205) 76.3 (187/245) 79.5 (155/195) 0.62
Travel distance to hospital (min., median,  
range; n = 648)
55 (2–360) 55 (3–360) 40 (5–300) 60 (2–300) 0.12
Mutooro ethnicity (%, No.) 58.9 (417/708) 53.2 (118/222) 61.4 (159/259) 61.9 (140/226) 0.10
Married (%, No.) 71.4 (517/724) 55.5 (126/227) 75.0 (201/268) 82.8 (188/227) <0.0001
Proportion without formal education (%, No.) 6.9 (49/715) 5.3 (12/228) 3.0 (8/264) 13.1 (29/221) <0.0001
Hospital cost coverage present (%, No.) 30.4 (207/682) 30.7 (66/215) 25.3 (65/257) 35.6 (74/208) 0.05
No. of people living in household  
(median, range; n = 706)
4.0 (1–22) 3.0 (1–12) 3.0 (1–11) 6.0 (2–22) <0.0001
Tap water on premises (%, No.) 40.9 (296/724) 40.2 (92/229) 48.9 (131/268) 31.9 (72/226) 0.0006
Electricity on premises (%, No.) 27.5 (199/723) 26.6 (61/229) 37.8 (101/267) 15.9 (36/226) <0.0001
Bed net in household (%, No.) 79.8 (574/719) 73.9 (167/226) 85.8 (230/268) 78.6 (176/224) 0.004
Antenatal care and malaria prevention
 No. of previous antenatal care visits  
(median, range; n = 657)
4.0 (0–9) 4.0 (0–7) 4.0 (0–9) 3.0 (0–8) 0.007
 Proportion with ≤3 antenatal care visits (%, No.) 42.9 (282/657) 42.0 (87/207) 36.9 (89/241) 50.5 (105/208) 0.01
 Participation in PMTCT programme (%, No.) 11.7 (85) 7.4 (17/229) 14.6 (39/268) 12.7 (29/228) 0.04
 Referred for delivery (%, No.) 46.4 (334/720) 51.3 (117/228) 41.9 (111/265) 46.5 (105/226) 0.11
 Slept under bed net last night (%, No.) 65.1 (436/670) 60.2 (127/211) 67.7 (170/251) 66.5 (137/206) 0.20
Malaria-preventive drug intake (%, No.)
 None 8.4 (58/688) 10.2 (22/216) 7.8 (20/258) 7.6 (16/211)
 IPTp 1 dose 25.6 (176/688) 30.6 (66/216) 20.9 (54/258) 26.1 (55/211)
 IPTp 2 doses 54.7 (376/688) 52.8 (114/216) 57.4 (148/258) 53.1 (112/211)
 Cotrimoxazole 7.8 (54/688) 3.2 (7/216) 11.2 (29/258) 8.5 (18/211)
 IPTp and cotrimaxazole 3.5 (24/688) 3.2 (7/216) 2.7 (7/258) 4.7 (10/211) 0.03
Week of gestation when taking IPTp dose 1  
(median, range; n = 548)
24 (8–38) 23 (8–38) 22 (12–38) 24 (12–36) 0.02
Week of gestation when taking IPTp dose 2  
(median, range; n = 365)
30 (20–40) 30 (21–39) 30 (20–40) 32 (20–39) 0.48
Received treatment for malaria episode during 
pregnancy (%, No.)
23.9 (164/685) 23.5 (51/217) 24.8 (63/254) 23.2 (49/211) 0.91
Clinical data
 Fever (%, No.) 1.0 (6/628) 1.0 (2/194) 0.9 (2/234) 1.0 (2/197) 0.98
 Haemoglobin (g/dL, median, range; n = 692) 12.5 (4.0–16.7) 12.6 (6.1–16.5) 12.6 (4.0–16.7) 12.2 (4.5–16.6) 0.17
 Anaemia (%, No.; Hb <11.5 g/dL) 28.9 (200/692) 27.9 (60/215) 26.5 (68/257) 33.2 (72/217) 0.25
 Birth weight (g; median, range; n = 709) 3100 (800–4720) 3000 (1100–4200) 3120 (900–4500) 3160 (800–4720) 0.0001
 Low birth weight (%, No.) 9.7 (69/709) 11.0 (24/219) 9.5 (25/263) 8.0 (18/225) 0.57
 Gestational age (weeks; mean ± SD; n = 705) 38.5 ± 2.1 38.3 ± 2.0 38.6 ± 2.2 38.6 ± 2.2 0.19
 Preterm delivery (%, No.) 11.9 (84/705) 15.9 (35/220) 8.8 (23/260) 11.7 (26/223) 0.06
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proved to be independent predictors of infection while 
age and household electricity were negatively associated 
(Table  5). Further, partly proximate, factors were not 
associated with infection, including parity, educational 
level, occupation, district of residence, number of people 
living in the household, other proxy indicator of socio-
economic status, number of antenatal care visits and 
participation in the PMTCT programme. In the above 
multivariate model, IPTp did not significantly influence 
the odds of P. falciparum infection (aOR, 0.59; 95 % CI, 
0.25–1.37; P = 0.22).
Molecular markers of drug resistance
Typing of essential pfdhfr and pfdhps alleles was suc-



























Fig. 1 Prevalence (%) of P. falciparum according to parity
Table 2 Low birth weight, preterm delivery, and maternal anaemia according to Plasmodium falciparum infection
OR odds ratio, 95 % CI 95 % confidence interval
Parameter Low birth weight Preterm delivery Anaemia
% (n/n) OR (95 % CI) P % (n/n) OR (95 % CI) P % (n/n) OR (95 % CI) P
P. falciparum PCR, peripheral blood
 Negative 9.0 (58/648) 1 10.8 (69/641) 1 27.0 (170/629) 1
 Positive 18.0 (11/61) 2.24 (1.0–4.7) 0.02 23.4 (15/64) 2.54 (1.3–5.0) 0.003 47.6 (30/63) 2.45 (1.4–4.3) 0.0006
P. falciparum infection
 None 9.0 (56/624) 1 10.0 (62/617) 1 26.9 (169/628) 1
 Submicroscopic 8.6 (3/35) 0.95 (0.2–3.2) 1.0 19.4 (7/36) 2.16 (0.8–5.3) 0.09 32.4 (12/37) 1.30 (0.6–2.8) 0.46
 Microscopic 30.8 (8/26) 4.51 (1.7–11.6) 0.002 28.6 (8/28) 3.58 (1.4–9.0) 0.007 70.4 (19/27) 6.45 (2.6–16.4) <0.0001
Table 3 Prevalence of P. falciparum infection according to the reported use of IPTp and/or cotrimoxazole
IPTP intermittent preventive treatment in pregnancy, CTX cotrimoxazole, OR odds ratio, 95 % CI 95 % confidence interval
Parameter None IPTp CTX IPTp + CTX No data
P. falciparum infection (PCR)
 %, No. 13.8 (8/58) 9.6 (53/552) 3.7 (2/54) 0 (0/24) 5.0 (2/40)
 OR (95 % CI), P Ref. 0.66 (0.3–1.6), P = 0.31 0.24 (0.0–1.3), P = 0.10 0 (0.0–1.4), P = 0.10 0.33 (0.0–1.8), P = 0.19
Placental parasitaemia
 %, No. 4.0 (2/50) 4.7 (24/515) 2.0 (1/51) 0 (0/23) 0 (0/37)
 OR (95 % CI), P Ref. 1.17 (0.3–10.5), P = 1.0 0.48 (0.0–9.6), P = 0.62 0.0 (0.0–11.7), P = 1.0 0.0 (0.0–7.2), P = 0.51
Maternal anaemia
 %, No. 26.4 (14/53) 27.4 (145/529) 38.0 (19/50) 26.1 (6/23) 43.2 (16/37)
 OR (95 % CI), P Ref. 1.05 (0.5–2.1), P = 0.88 1.71 (0.7–4.3), P = 0.21 0.98 (0.3–3.3), P = 0.98 2.12 (0.8–5.7), P = 0.10
Low birth weight
 %, No. 13.8 (8/58) 9.5 (51/535) 9.3 (5/54) 8.3 (2/24) 7.9 (3/38)
 OR (95 % CI), P Ref. 0.66 (0.3–1.6), P = 0.3 0.64 (0.2–2.4), P = 0.45 0.57 (0.1–3.2), P = 0.72 0.54 (0.1–2.5), P = 0.52
Preterm delivery
 %, No. 10.7 (6/56) 11.4 (61/534) 17.0 (9/53) 13.0 (3/23) 12.8 (5/39)
 OR (95 % CI), P Ref. 1.07 (0.4–3.2), P = 0.87 1.70 (0.5–6.3); P = 0.34 1.25 (0.2–6.6), P = 0.71 1.23 (0.3–5.3), P = 0.76
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in ≥95 % each for pfdhfr codons 51, 59, and 108 as well 
as for pfdhps codons 437 and 540 (Fig.  2). In conse-
quence, pfdhfr/pfdhps quintuple and sextuple mutations 
were observed in 93  % (51/55) of the isolates. The high 
resistance alleles pfdhfr 164L and pfdhps 581G occurred 
each in 36 % (18/50; 20/55); pfdhps 581G in 42 % (8/19) 
occurred together with pfdhfr 164L. pfdhps 581G was 
associated with increased placental parasitaemia as com-
pared to wildtype parasites, both in the overall group 
[GMPD, 22/100 high power fields; 95  % CI, 7–70 vs. 4 
Table 5 Factors associated with P. falciparum infection
OR odds ratio, aOR adjusted OR, 95 % CI 95 % confidence interval
a Adjusted for other factors significantly associated with outcome; n = 643
Parameter No. % Infected Univariate analysis Multivariate analysisa
OR (95 % CI) P aOR (95 % CI) P
Age (years) 728 n.a. 0.93 (0.88–0.98) 0.005 0.94 (0.89–0.99) 0.02
Referred for delivery
 No 386 5.2 1
 Yes 334 13.2 2.78 (1.55–5.0) 0.0002 2.11 (1.17–3.81) 0.01
Travel distance to hospital
 ≤1 h 477 7.3 1
 >1 h 171 15.2 2.26 (1.27–4.02) 0.003 1.80 (1.02–3.17) 0.04
Electricity on the premises
 No 524 11.1 1
 Yes 199 3.5 0.29 (0.11–0.66) 0.002 0.38 (0.17–0.86) 0.02
Used bet net last night
 No 234 12.8 1
 Yes 436 6.9 0.50 (0.29–0.88) 0.01
Bed net ownership
 No 145 13.8 1
 Yes 574 7.8 0.53 (0.29–0.97) 0.03
Ethnic group
 Mutooro 417 7 1






















Fig. 2 Prevalence (%) of pfdhfr and pfdhps mutations in 55 P. falciparum isolates from western Uganda. Asterisk n = 50. Sextuple mutation is dis-
played in black
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(2–7), P = 0.01] and among women who had been taking 
IPTp [25 (7–87) vs. 4 (2–9), P = 0.02].
Discussion
In this highland area of western Uganda, though malaria 
in pregnancy is comparatively rare, it substantially con-
tributes to mortality and morbidity including stillbirth, 
early neonatal death, anaemia, LBW and preterm deliv-
ery. IPTp, recommended for the prevention of malaria 
and its consequences, did not show a beneficial effect. 
One very likely reason is the vast predominance of highly 
resistant strains of P. falciparum.
The protective efficacy of IPTp with SP against placen-
tal malaria has been estimated as roughly 50 % in areas 
of low to moderate SP resistance and over a decade ago 
[32]. As a major limitation, the present cross-sectional 
study lacked power to display an only modest impact of 
IPTp. Considering the given group sizes and prevalence, 
the study was powered to detect an effect of IPTp on P. 
falciparum infection at a magnitude of >75 % reduction. 
Nevertheless, infection prevalence was actually higher in 
women having taken two as compared to one dose of SP, 
and placental parasitaemia, anaemia, and preterm deliv-
ery were slightly more common in women having taken 
IPTp as compared to women without drug-based preven-
tion. A further limitation refers to the validity of reported 
IPTp use on which the current analysis is based. How-
ever, in Tanzania, reported use and detection of plasma 
sulfa levels matched closely [11] suggesting that reported 
use is not unreliable per se. It appears, therefore, justifi-
able to state that IPTp did not fulfil its purpose. Because 
HIV negativity has yet to be confirmed by molecular 
means in the study group, participation in a PMTCT 
programme was considered as a proxy indicator of HIV 
status. PMTCT participation and cotrimoxazole intake 
overlapped largely. It is, therefore, not possible to make 
firm statements on an impact of HIV infection on P. falci-
parum infection or pregnancy outcomes but the analyses 
do not provide evidence for respective effects. Also, data 
on some potentially interfering factors were not available, 
e.g., syphilis. This should be kept in mind when interpret-
ing the data.
Plasmodium falciparum infection was detected by 
microscopy of peripheral and placental blood films in 
only 3 and 4 %, respectively. Peripheral blood microscopy 
is notoriously insensitive in pregnant women whereas 
the sensitivity of PCR assays in detecting placental para-
sitaemia exceeds 95 % [4]. Submicroscopic infections in 
pregnancy are common and may contribute substantially 
to maternal and foetal morbidity [3, 4, 33]. In the pre-
sent study, however, they did not associate with delivery 
outcomes, with the potential exemption of a borderline 
increased risk of preterm delivery. In contrast, malaria in 
pregnancy per se greatly increased the odds of stillbirth, 
early neonatal death, anaemia, LBW and preterm deliv-
ery. Even if comparatively rare at 9 %, this emphasizes the 
need for effective prevention of malaria in pregnancy in 
the study area. Peripheral residence and lacking electric-
ity predicted P. falciparum infection illustrating the pov-
erty-related nature of malaria. Bed net use, even though 
not significantly associated in multivariate analysis, was 
stated by almost two thirds of women and roughly halved 
the odds of infection. This highlights the opportunity 
and benefits of increasing bed net use among pregnant 
women in the study area.
Beyond statistical significance, P. falciparum preva-
lence was greatly reduced in women on cotrimoxazole 
and absent in those taking both cotrimoxazole and IPTp. 
This accords with findings from Malawi [34]. A slight 
superiority of daily cotrimoxazole over IPTp with SP in 
HIV-infected pregnant women was also observed in Togo 
[35] whereas the regimens had similar effects in Uganda 
[36] and Zambia [37]. Data of the present study, although 
comprising small numbers only, support the policy of 
using daily cotrimoxazole for malaria prevention in 
HIV-infected pregnant women instead of SP-IPTp. As a 
matter of fact, IPTp with SP is not recommended in HIV-
infected women receiving daily cotrimoxazole because of 
additive sulfa toxicity [38].
Resistance marker typing in peripheral blood is reason-
ably representative of P. falciparum infecting pregnant 
women [39]. In the present study, pfdhfr/pfdhps quintu-
ple mutants were close to fixation, and sextuple mutants 
and the high-grade resistance allele pfdhfr 164L occurred 
in one third of isolates. This accords with recent data 
from pregnant women in central Uganda [24], with one 
notable exception: there, only few parasites exhibited 
the pfdhps 581G mutation even though the proportion 
increased after IPTp. Consequently, in central Uganda, 
sextuple mutants made up less than a third of the pro-
portion observed in Fort Portal. Against a background of 
intense antifolate resistance, this indicates an even higher 
degree in the present study area. The pfdhps 581G muta-
tion (making up the sextuple mutant) has been consid-
ered to halve the protective period provided by a curative 
dose of SP [14] and to be associated with reduced birth 
weights and an increased risk of patent infection among 
mothers taking IPTp [16, 22]. In the present study, it 
was associated with increased placental parasite den-
sity, which accords with recent findings from Malawi 
[22]. Recent work has shown that this mutation has 
occurred multiple times on local pfdhps double-mutant 
backgrounds [40] and emerges in East Africa [41–45]. 
Moreover, in the present study, the pfdhfr 164L mutation 
occurred in 36  %, which is the highest figure reported 
from Africa [6, 18]. A previous study from southwestern 
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Uganda found this high-grade resistance allele in 4  % 
and 14  % [43]. Even though the molecular data suggest 
intense SP resistance in the study area, the actual mean-
ing for IPTp is not clear-cut. In central Uganda, despite 
>98  % pfdhfr/pfdhps quintuple mutants (but at a low 
prevalence of pfdhps 581G), 50  % of initially P. falcipa-
rum infected pregnant women became negative after 
one or two rounds of IPTp [24]. A current meta-analysis 
suggests a prevalence threshold of pfdhps 581G at which 
IPTp no longer protects against LBW of >10.1  % [21]. 
WHO recently considered the discontinuation of IPTp 
with SP in case of P. falciparum population prevalences 
of pfdhps 540E >95 % and pfdhps 581G >10 % [20]. In the 
present study, these thresholds are basically met (pfdhps 
540E, 94.5 %; 581G, 36 %).
What then could be alternatives for the prevention of 
malaria in pregnancy in the study area? IPTp with meflo-
quine has disappointed expectations [46] and is not 
recommended [20]. WHO advises that in areas where 
IPTp-SP is discontinued because of resistance, access of 
pregnant women to long-lasting insecticide treated nets 
and to prompt diagnosis and effective treatment should 
be ensured. In the study area, bed net use can in fact be 
increased. Diagnosis, preferentially with a sensitive anti-
gen capture test [4], preceding case management requires 
an easily accessible health system and an alert population. 
The same applies to the concept of intermittent screen-
ing and treatment [47]. Moreover, for both approaches, 
the issue of asymptomatic but still deleterious infections 
remains unsolved. Artemisinin-based combination ther-
apy (ACT) is recommended for the treatment of malaria 
in pregnancy [38] but their use in IPTp has not been eval-
uated and may be complicated by the necessity of a 3-day 
regimen.
Conclusion
Malaria in pregnancy in the area of Fort Portal, western 
Uganda, is comparatively rare but contributes signifi-
cantly to stillbirth, anaemia, LBW, and preterm deliv-
ery. The molecular markers of P. falciparum show a very 
high degree of SP resistance, and reach the threshold 
set by WHO for the discontinuation of IPTp with SP. In 
line with that, IPTp with SP did not provide an observ-
able benefit. Alternative approaches for the prevention of 
malaria in pregnancy are urgently needed.
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